Edition:
India

Aptinyx Inc (APTX.OQ)

APTX.OQ on NASDAQ Stock Exchange Global Select Market

4.28USD
1:27am IST
Change (% chg)

$0.08 (+1.90%)
Prev Close
$4.20
Open
$4.20
Day's High
$4.29
Day's Low
$4.07
Volume
17,312
Avg. Vol
29,015
52-wk High
$22.63
52-wk Low
$2.61

Latest Key Developments (Source: Significant Developments)

Aptinyx Inc - QTRLY Loss Per Share $0.44
Wednesday, 13 Nov 2019 

Aptinyx Inc ::APTINYX REPORTS THIRD QUARTER 2019 FINANCIAL RESULTS AND HIGHLIGHTS.APTINYX INC - INITIATED TWO PHASE 2 STUDIES OF NYX-2925 IN CHRONIC PAIN CONDITIONS.APTINYX INC - QTRLY LOSS PER SHARE $0.44.  Full Article

Aptinyx Initiates Two Phase 2 Studies Of Nyx-2925 In Patients With Chronic Centralized Pain Conditions
Tuesday, 12 Nov 2019 

Nov 12 (Reuters) - Aptinyx Inc ::APTINYX INITIATES TWO PHASE 2 STUDIES OF NYX-2925 IN PATIENTS WITH CHRONIC CENTRALIZED PAIN CONDITIONS.APTINYX INC - TOP-LINE EFFICACY AND SAFETY DATA ANTICIPATED IN LATE 2020 OR EARLY 2021 FOR PAINFUL DPN AND 1H 2021 FOR FIBROMYALGIA.APTINYX- EXPECTS TO REPORT DATA FROM PAINFUL DPN STUDY IN LATE 2020 OR EARLY 2021, AND FROM FIBROMYALGIA STUDY IN FIRST HALF OF 2021.  Full Article

Aptinyx Reports Qtrly Loss Per Share Of $0.50
Tuesday, 14 May 2019 

May 14 (Reuters) - Aptinyx Inc ::APTINYX REPORTS FIRST QUARTER 2019 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.APTINYX INC - FOUR PHASE 2 STUDIES EXPECTED TO BE ONGOING BY YEAR END; MULTIPLE DATA READ-OUTS ANTICIPATED IN 2019 AND 2020.APTINYX INC QTRLY LOSS PER SHARE $0.50.APTINYX INC - CASH AND CASH EQUIVALENTS WERE $136.6 MILLION AT MARCH 31, 2019 COMPARED TO $150.6 MILLION AT DECEMBER 31, 2018..  Full Article

Aptinyx Reports Robust Analgesic Activity Of Its NYX-2925 In Advanced DPN Patients
Thursday, 18 Apr 2019 

April 18 (Reuters) - Aptinyx Inc ::ROBUST ANALGESIC ACTIVITY OF APTINYX’S NYX-2925 IN ADVANCED DPN PATIENTS REVEALED THROUGH FURTHER ANALYSIS OF DATA FROM PHASE 2 STUDY.APTINYX INC - RESULTS SUPPORT AND INFORM FUTURE PHASE 2 STUDY, INITIATION EXPECTED IN 2019.APTINYX INC - MECHANISM OF NYX-2925 IS HIGHLY RELEVANT IN ADVANCED DPN PATIENTS WITH LONGER DURATION OF CHRONIC PAIN.  Full Article

Aptinyx Q4 Loss Per Share $0.42
Thursday, 21 Mar 2019 

March 21 (Reuters) - Aptinyx Inc ::APTINYX REPORTS FOURTH QUARTER AND FULL YEAR 2018 FINANCIAL RESULTS AND HIGHLIGHTS PIPELINE AND BUSINESS PROGRESS.Q4 LOSS PER SHARE $0.42.Q4 EARNINGS PER SHARE ESTIMATE $-0.50 -- REFINITIV IBES DATA.COMPLETED PHASE 2 STUDY OF NYX-2925 IN PAINFUL DPN WHICH DID NOT MEET PRIMARY ENDPOINT.INITIATED FIRST-IN-PATIENT PHASE 2A STUDY OF NYX-783 IN PATIENTS WITH PTSD WITH DATA EXPECTED IN 1H 2020.NEARING COMPLETION OF PHASE 1 STUDY OF NYX-458 IN HEALTHY VOLUNTEERS WITH DATA EXPECTED IN 1H 2019.CASH AND CASH EQUIVALENTS WERE $150.6 MILLION AT DECEMBER 31, 2018 COMPARED TO $92.1 MILLION AT DECEMBER 31, 2017..  Full Article

Aptinyx Inc Initiates Phase 2 Study To Evaluate Safety And Efficacy Of NYX-783 In Patients With Post-Traumatic Stress Disorder
Tuesday, 19 Feb 2019 

Feb 19 (Reuters) - Aptinyx Inc ::APTINYX INITIATES PHASE 2 STUDY TO EVALUATE SAFETY AND EFFICACY OF NYX-783 IN PATIENTS WITH POST-TRAUMATIC STRESS DISORDER.APTINYX INC - PHASE 2 DATA ANTICIPATED 1H 2020.APTINYX INC - DOSED FIRST PATIENT IN A PHASE 2 STUDY OF NYX-783 FOR TREATMENT OF POST-TRAUMATIC STRESS DISORDER.APTINYX INC - FAVORABLE SAFETY AND TOLERABILITY, LINEAR PHARMACOKINETICS, AND AMPLE CNS EXPOSURE OF NYX-783 OBSERVED IN PHASE 1.  Full Article

Aptinyx Sees IPO Of 5.3 Mln Shares Priced To Be Between $14 And $16 Per Share – SEC Filing
Monday, 11 Jun 2018 

June 11 (Reuters) - Aptinyx Inc ::APTINYX INC SEES IPO OF 5.3 MILLION SHARES PRICED TO BE BETWEEN $14 AND $16 PER SHARE – SEC FILING.  Full Article